ACME Laboratories (DHA:ACMELAB) Owner Earnings per Share (TTM): 7.14 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DHA:ACMELAB ACME Laboratories Ltd DHA:ACMELAB
85 GF Score
Price BDT79.80
GF Value BDT128.04
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is ACME Laboratories Owner Earnings per Share (TTM)?

ACME Laboratories DHA:ACMELAB +0.13% 85 Owner Earnings per Share (TTM) is 7.14 as of Mar. 2026. GuruFocus rates DHA:ACMELAB with a GF Score™ of 85/100 and a GF Value™ of BDT128.04 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 463 Drug Manufacturers companies, ACME Laboratories ranks better than 76.03% on this metric.

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

ACME Laboratories's Owner Earnings per Share (TTM) ended in Mar. 2026 was BDT7.14. It's Price-to-Owner-Earnings ratio for today is 11.18.


The historical rank and industry rank for ACME Laboratories's Owner Earnings per Share (TTM) or its related term are showing as below:

DHA:ACMELAB' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 5.41   Med: 6.58   Max: 11.94
Current: 11.35


During the past 9 years, the highest Price-to-Owner-Earnings ratio of ACME Laboratories was 11.94. The lowest was 5.41. And the median was 6.58.


DHA:ACMELAB's Price-to-Owner-Earnings is ranked better than
76.03% of 463 companies
in the Drug Manufacturers industry
Industry Median: 23.09 vs DHA:ACMELAB: 11.35

ACME Laboratories's Earnings per Share (Diluted) for the three months ended in Mar. 2026 was BDT3.30. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was BDT9.41. It's PE Ratio (TTM) ratio for today is 8.48.

ACME Laboratories's EPS without NRI for the three months ended in Mar. 2026 was BDT3.30. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was BDT9.41. It's PE Ratio without NRI ratio for today is 8.48.


Be Aware

Assumption: Companies usually do not report maintenance capital expenditures and growth capital expenditures separately. Here we use estimated numbers and average them over 5 years. The method to estimate maintenance capital expenditures can be found in above part 4.

Note: GuruFocus' Change In Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And it includes non-current parts of assets and liabilities.


ACME Laboratories Owner Earnings per Share (TTM) Related Terms


ACME Laboratories Owner Earnings per Share (TTM) Historical Data

* Premium members only.

The historical data trend for ACME Laboratories's Owner Earnings per Share (TTM) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ACME Laboratories Owner Earnings per Share (TTM) Chart

ACME Laboratories Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Owner Earnings per Share (TTM)
Get a 7-Day Free Trial Premium Member Only 0.00 -2.41 14.58 -10.04 -7.03

ACME Laboratories Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Sep25 Dec25 Mar26
Owner Earnings per Share (TTM) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -6.78 -6.83 -3.20 -0.50 7.14

DHA:ACMELAB vs ZTS, UTHR, VTRS: Owner Earnings per Share (TTM) Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, ACME Laboratories's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ACME Laboratories Price-to-Owner-Earnings vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, ACME Laboratories's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where ACME Laboratories's Price-to-Owner-Earnings falls into.


DHA:ACMELAB
85GF Score
ACME Laboratories Ltd DHA:ACMELAB
Owner Earnings per Share (TTM) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ACME Laboratories Owner Earnings per Share (TTM) Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

To make it simple, then you will have:

Owner Earnings per Share (TTM) = (Net Income + Depreciation, Depletion and Amortization + Change In Deferred Tax - 5Y Average of Maintenance Capital Expenditure + Change In Working Capital) / Shares Outstanding (Diluted Average)

ACME Laboratories's Owner Earnings per Share (TTM) Calculation:

TTM / Last Quarter Average of Last 20 Quarters
Net Income 1,990
Depreciation, Depletion and Amortization 1,831
Change In Deferred Tax 0
5Y Average of Maintenance Capital Expenditure 2,163
Change In Working Capital -148
Shares Outstanding (Diluted Average) 211

1. Start with "Net Income" from income statement. ACME Laboratories's Net Income for the trailing twelve months (TTM) ended in Mar. 2026 was BDT1,990 Mil.

2. "Depreciation, Depletion and Amortization" is from cashflow statement. ACME Laboratories's Depreciation, Depletion and Amortization for the trailing twelve months (TTM) ended in Mar. 2026 was BDT1,831 Mil. This needs to be added back because company does not actually need to pay cash for it. It is a non-cash item.

3. Other non-cash charges usually include "Stock Based Compensation" and "Change In Deferred Tax":
However, to be conservative, GuruFocus will not add Stock Based Compensation back to net income. ACME Laboratories's Change In Deferred Tax for the trailing twelve months (TTM) ended in Mar. 2026 was BDT0 Mil.

4. Average maintenance capital expenditure over a business/industry cycle: 5-Year Average Maintenance Capital Expenditure = BDT2,163 Mil

It is usually best to take a long-term average of maintenance capital expenditure. Ideally this would be as long as 10 years and include at least one economic downturn. However, since many companies do not have as long as 10-year history, here GuruFocus uses the latest 5 years data to do the calculation. To smooth out unusual years but reflect recent developments, we take an average of the 5 year maintenance capital expenditure.

The following shows how to get maintenance capital expenditure.

First, calculate the revenue change regarding to the previous quarter. If the revenue decreased from the previous quarter, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
Second, if the revenue increased from the previous quarter, then calculate the percentage of Net PPE as of corresponding Revenue.
Growth Capital Expenditure = Percentage of Property, Plant and Equipment as of corresponding Revenue * Revenue Increase
Third, calculate Capital Expenditure (positive) - Growth Capital Expenditure.
If [Capital Expenditure (positive) - Growth Capital Expenditure] was negative, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
If [Capital Expenditure (positive) - Growth Capital Expenditure] was positive, then the Maintenance Capital Expenditure = Capital Expenditure (positive) - Growth Capital Expenditure.
Fourth, get the average of the 5 years maintenance capital expenditure.

ACME Laboratories's 5-Year Average Maintenance Capital Expenditure = BDT2,163 Mil

5. "Change In Working Capital" is from cashflow statement. ACME Laboratories's Change In Working Capital for the trailing twelve months (TTM) ended in Mar. 2026 was BDT-148 Mil.
Note: GuruFocus' Change in Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And sometimes it includes non-current parts of assets and liabilities.

6. ACME Laboratories's Shares Outstanding (Diluted Average) for the months ended in Mar. 2026 was 211.482 Mil.

ACME Laboratories's Onwer Earnings Per Share for Mar. 2026 is calculated as:

Owner Earnings per Share (TTM)
=( Net Income+Depreciation, Depletion and Amortization+Change In Deferred Tax
=( 1990.049 +1831.42+0
-5Y Avg of Maintenance CAPEX+Change In Working Capital )/Shares Outstanding (Diluted Average)
-2162.6269998509+-148.013)/211.482
=7.14

Price-to-Owner-Earnings=Current Price/Owner Earnings per Share (TTM)
=79.80/7.14
=11.18

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Owner Earnings per Share (TTM) of 7.14 mean?
ACME Laboratories (DHA:ACMELAB) has a Owner Earnings per Share (TTM) of 7.14 as of Mar. 2026. Warren Buffett defined owner earnings as reported earnings plus depreciation less average maintenance capital expenditure. View historical data on ACME Laboratories. According to the industry distribution chart, ACME Laboratories ranks #111 out of 463 companies in the Drug Manufacturers industry, placing it in the top 24%.
Is ACME Laboratories' Owner Earnings per Share (TTM) too high?
ACME Laboratories' current Owner Earnings per Share (TTM) is 7.14. The Drug Manufacturers industry median Owner Earnings per Share (TTM) is 23.09. ACME Laboratories' value of 7.14 is 69.1% below this industry median. Based on the distribution chart, ACME Laboratories ranks #111 out of 463 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, ACME Laboratories has a GF Score™ of 85/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does ACME Laboratories' Owner Earnings per Share (TTM) compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, ACME Laboratories ranks #111 out of 463 companies for Owner Earnings per Share (TTM). This places ACME Laboratories in the top 24% of its industry — outperforming the majority of peers. The industry median Owner Earnings per Share (TTM) is 23.09. ACME Laboratories' value of 7.14 is 69.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Owner Earnings per Share (TTM) for a Drug Manufacturers company?
The median Owner Earnings per Share (TTM) among Drug Manufacturers companies is 23.09, based on 463 companies in the industry. Companies in the top quartile (top 25%) have a Owner Earnings per Share (TTM) significantly above this median, while those in the bottom quartile fall well below. However, Owner Earnings per Share (TTM) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ACME Laboratories's current Owner Earnings per Share (TTM) of 7.14 is 69.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Owner Earnings per Share (TTM) mean?
A high Owner Earnings per Share (TTM) can signal that a stock is expensive relative to its fundamentals. Warren Buffett defined owner earnings as reported earnings plus depreciation less average maintenance capital expenditure. View historical data on ACME Laboratories. For the Drug Manufacturers industry, the median Owner Earnings per Share (TTM) is 23.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ACME Laboratories's current Owner Earnings per Share (TTM) is 7.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ACME Laboratories stock overvalued right now?
Based on GuruFocus' analysis, ACME Laboratories (DHA:ACMELAB) is currently considered Possible Value Trap. The stock's GF Value™ is BDT128.04, compared to a current price of BDT79.80 — trading 37.7% below its estimated fair value. The current Owner Earnings per Share (TTM) is 7.14 and 69.1% below the Drug Manufacturers industry median of 23.09. ACME Laboratories' overall GF Score™ is 85/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Owner Earnings per Share (TTM) calculated?
Owner Earnings per Share (TTM) is calculated from a company's financial statements. For ACME Laboratories (DHA:ACMELAB), the current Owner Earnings per Share (TTM) is 7.14 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ACME Laboratories (DHA:ACMELAB) Overvalued in 2026?

Based on GuruFocus' analysis, ACME Laboratories stock appears to be undervalued. The current stock price of BDT79.80 is trading 37.7% below its estimated GF Value™ of BDT128.04. GuruFocus considers ACME Laboratories to be Possible Value Trap.

Key valuation signals for DHA:ACMELAB:

  • Owner Earnings per Share (TTM): 7.14
  • GF Value™: BDT128.04 vs. price of BDT79.80 (37.7% below fair value)
  • GF Score™: 85/100 with 7 warning signs
  • Industry Position: 69.1% below the Drug Manufacturers median (#111 of 463)

No single metric tells the full story. See the DHA:ACMELAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


ACME Laboratories Business Description

Address 1/4, Kallayanpur, Mirpur Road, Court de la ACME, Dhaka, BGD, 1207
ACME Laboratories Ltd is engaged in the manufacturing, marketing, and distribution of generic pharmaceutical products in Bangladesh. The Company is engaged in manufacturing, marketing, and distribution of generic pharmaceuticals formulation products which includes human drugs comprising dosages form like a tablet, capsule, dry syrup, cream, ointment, powder, injection, dry powder inhaler, metered dosage inhaler, suppository, eye and nasal drop, liquid, liquid in hard gelatine, Blow Fill Seal (BFS) products, sachet products; veterinary drugs comprising dosages form like bolus, liquid,injection, water-soluble powder, premix and herbal drugs comprising dosages form like liquid, capsule, tablet, cream. The products of the company are sold in domestic and international markets.
85GF Score

Get the complete analysis for DHA:ACMELAB

Owner Earnings per Share (TTM) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

BDT79.80
Price
BDT128.04
GF Value